Phase I first-in-man dose-escalation study of the tolerability, maximum tolerated dose, pharmacokinetics and preliminary efficacy of rigosertib in patients with advanced cancer
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2008
At a glance
- Drugs Rigosertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Onconova Therapeutics
- 29 Oct 2008 Results published online in the Journal of Clinical Oncology, according to a Onconova Therapeutics media release.
- 29 Oct 2008 Status changed from planning to completed according to a Onconova media release.
- 24 Apr 2007 New trial record.